Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKF7G0
|
|||
| Drug Name |
Glofitamab
|
|||
| Synonyms |
RG6062
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Approved | [1] | |
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1 | [2] | ||
| Company |
Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Modulator | [1] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Modulator | [1] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309 | |||
| REF 2 | ClinicalTrials.gov (NCT04246086) A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.